- FIH phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumorsQiu, M.; Guo, Y.; Guo, W.; Nian, W.; Liao, W.; Xu, Z.; Zhang, W.; Zhang, Y.; Wei, X.; Xue, L.; Tang, W.; Wu, Y.; Ren, G.; Wang, L.; Xi, J.; Wang, Y.; Li, M.; Hausheer, F.; Hu, C.; Xu, R.Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2021-09-16 To 2021-09-21.
- Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomasP. SMILEK; J. NEUWIRTHOVA; J. JARKOVSKY; L. DUSEK; J. ROTTENBERG; R. KOSTRICA; J. SROVNAL; M. HAJDUCH; J. DRABEK; J. KLOZARNeoplasma, 2012, 59(05): 508-515.
- Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ib study.Yang, Hang; Wang, Xicheng; Zhang, Hong; Peng, Jiyong; Li, Weidong; Liu, Yanyan; Hu, Jianbing; Zhou, Hui; Zhang, Bing; Liu, Jixiang; Lin, Shunhuan; Luo, Hao; Hu, Jie; Li, ZhimingAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
会议论文
Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
7阅读
